calcitriol IV
Selected indexed studies
- Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline. (J Clin Endocrinol Metab, 2023) [PMID:36545746]
- Hypocalcemia-Induced Reversible Psychosis. (Cureus, 2022) [PMID:35145781]
- Calcitriol resistance in hemodialysis patients with secondary hyperparathyroidism. (Int Urol Nephrol, 2014) [PMID:24384877]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline. (2023) pubmed
- Hypocalcemia-Induced Reversible Psychosis. (2022) pubmed
- Calcitriol resistance in hemodialysis patients with secondary hyperparathyroidism. (2014) pubmed
- Novel adjuvant systems. (2001) pubmed
- Hypercalcemia of Malignancy: Mechanisms and Therapeutic Implications of Concurrently Elevated PTHrP and Calcitriol. (2025) pubmed
- Vitamin D and Cardiac Differentiation. (2016) pubmed
- No difference in intestinal strontium absorption after oral or IV calcitriol in children with secondary hyperparathyroidism. The European Study Group on Vitamin D in Children with Renal Failure. (2000) pubmed
- Calcitriol attenuates poly(I:C)-induced lung injury in obese mice via modulating toll-like receptor 3- and renin-angiotensin system-associated signal pathways. (2024) pubmed
- CCL20 expression is elevated in inflammatory bowel disease and attenuated by vitamin D metabolites. (2025) pubmed
- BISPHOSPHONATES FOR THE TREATMENT OF CALCITRIOL-INDUCED HYPERCALCEMIA. (2019) pubmed